PDF(Pubmed)
Abstract：
The rapid development of high-throughput sequencing in recent years has facilitated great progress in the molecular-targeted therapy of hematological malignancies, including leukemia, lymphoma, and multiple myeloma. BCL-2 inhibitors are among the most important molecular-targeted agents. Immunotherapy for hematologic malignancy has rapidly increased in popularity in recent years and has been proven to improve the overall survival rate. However, few clinical studies have investigated combination therapy with BCL-2 inhibitors and immunotherapies, such as immune molecule-targeted drugs or immune cell adoptive therapy. In this review, we discuss the drug discovery process, current clinical application status, and resistance and tolerance issues associated with BCL-2 inhibitors. We emphasize their important role in regulating the immune system and propose that the combination of BCL-2 inhibitors with immunotherapy may be one of the most promising treatment methods for hematologic malignancies.
摘要：
近年来高通量测序技术的快速发展促进了血液系统恶性肿瘤分子靶向治疗的重大进展,包括白血病,淋巴瘤和多发性骨髓瘤.BCL-2抑制剂是最重要的分子靶向药物之一。近年来，恶性血液病的免疫治疗迅速普及，并已被证明可以提高整体生存率。然而,很少有临床研究研究BCL-2抑制剂和免疫疗法的联合治疗，如免疫分子靶向药物或免疫细胞过继治疗。在这次审查中,我们讨论药物发现过程，临床应用现状,以及与BCL-2抑制剂相关的耐药性和耐受性问题。我们强调它们在调节免疫系统中的重要作用，并提出BCL-2抑制剂与免疫治疗的组合可能是血液系统恶性肿瘤最有前途的治疗方法之一。
